Global 3D Bioprinting Market Value Projected To Reach USD 2.84 Billion By 2027, Registering A CAGR Of 20.3% – Digital Journal
stemadminStem Cell ResearchNo comments

Global 3D Bioprinting MarketIs Expected To Reach USD 2.84 Billion By 2027 At A CAGR Of 20.3 percent. Maximize Market Research has published a report on theGlobal 3D Bioprinting Marketthat provides a detailed analysis for the forecast period of 2022 to 2027. Global 3D Bioprinting MarketScope: The report provides comprehensive market insights for industry stakeholders, including an explanation of complicated market data in simple language, the industrys history and present situation, as well as expected market size and trends

Read more
Cell Expansion Market Projection By Top Key Players, Regional Analysis Revenue Forecast Till 2030 Designer Women – Designer Women
stemadminStem Cell ResearchNo comments

New York(United States):- According to Report Ocean research report Global Cell Expansion Market: Analysis By Product Type (Instruments, Consumables, Disposables), By Cell Type (Human Cell and Animal Cell), By Application (Regenerative Medicine & Stem Cell Research and Cancer & Cell Based Research), By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa), (U.S, Canada, Germany, France, U.K., Japan, China, India): Opportunities and Forecast (2019 Edition): Forecast to 2024-, the cell expansion market is projected to display a robust growth represented by a CAGR of 17.33% during 2019 2024. A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of cell expansion market. The report analyses the Global Cell Expansion Market: Analysis By Product Type (Instruments, Consumables, Disposables), By Cell Type (Human Cell and Animal Cell), By Application (Regenerative Medicine & Stem Cell Research and Cancer & Cell Based Research), By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa), (U.S, Canada, Germany, France, U.K., Japan, China, India): Opportunities and Forecast (2019 Edition): Forecast to 2024, for the historical period of 2018-2019 and the forecast period of 2019-2024.

Read more
Organoids reveal similarities between myotonic dystrophy type 1 and Rett syndrome – EurekAlert
stemadminStem Cell ResearchNo comments

Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy, characterized by progressive muscle wasting and weakness and caused by abnormally repetitive DNA segments that are transcribed into toxic molecules of RNA. Instead of ferrying a gene's instructions for translation into proteins, these RNA molecules accumulate in cells, disrupting cellular machinery

Read more
Cell Separation Technology Market Size, Scope and Forecast | Beckman Coulter, Becton, Dickinson and Company, GE Healthcare, Merck KGaA, Miltenyi…
stemadminStem Cell ResearchNo comments

New Jersey, United States This Cell Separation Technology Market research examines the state and future prospects of the Cell Separation Technology market from the perspectives of competitors, regions, products, and end Applications/industries. The Worldwide Cell Separation Technology market is segmented by product and Application/end industries in this analysis, which also analyses the different players in the global and key regions.

Read more
Novartis hunting for sickle cell cure with Precision deal – BioPharma Dive
stemadminStem Cell ResearchNo comments

Dive Brief: Sickle cell and beta thalassemia, both rare, life-threatening diseases caused by mistakes in DNA, are top targets for biotech and pharma companies working in the genetic medicine field. Several of those efforts have advanced to, or will soon reach, the Food and Drug Administration. Earlier this month, advisers to the agency recommended approval for a cell-based gene therapy designed by Bluebird bio to treat beta thalassemia

Read more
BRIM Biotechnology enters OTC trading in Taiwan – Bio-IT World
stemadminStem Cell ResearchNo comments

Taipei, Taiwan, 23rdJune 2022 /SciadNewswire/BRIM Biotechnology, Inc.(BRIM, TWSE 6995) enters OTC trading in Taiwan on 23rdJune 2022, CST. The news was announced at the companys first earnings call on 22ndJune 2022. Established in July 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases

Read more

Theme: Illdy.